Alopecia Areata: From Pathophysiology to Therapeutic Innovation

April 2023 in “ Portuguese Journal of Dermatology and Venereology ”

Nuno Lourenço, Margarida Gonçalo

alopecia areata immune privilege interferon-gamma JAK-STAT pathway JAK inhibitors baricitinib tofacitinib ruxolitinib ritlecitinib brepocitinib phosphodiesterase-4 inhibitors dupilumab Olumiant

Studysummary This review examines the pathophysiological mechanisms and emerging targeted treatments for alopecia areata, particularly highlighting the efficacy of oral JAK inhibitors over other less effective alternatives.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

Read the full study on portuguesejournalofdermatology.com →

Related research 1

Related Community Posts